Urinary Incontinence Sector Misses Opportunities in the SUI and IC Markets While UUI Market Becomes Crowded.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c41991) has announced the addition of Management of Urinary Incontinence and Overactive Bladder - A Global Overview to their offering.

Although there are many marketed treatments for overactive bladder, there are few available for stress urinary incontinence or interstitial cystitis. Furthermore, despite available treatments for overactive bladder, many are associated with side effects leading to poor treatment compliance. With significant unmet needs remaining in these markets, there are clear opportunities for new entrants.

Scope of this title:

--Overview of epidemiology, presentation and referral patterns, and diagnostic assessment for UUI, SUI, MUI, dry OAB, and IC

--Role and use of non-pharmacological versus pharmacological treatment for UUI, SUI, MUI, dry OAB, and IC

--In-fluences on treatment choice and perception of current drug therapies including tolterodine, oxybutynin, darifenacin, solifenacin and duloxetine

--Evaluation of unmet needs and future outlook including awareness of the R&D drug pipeline

Highlights of this title:

--Drug therapy for urinary disorders has predominantly focused on the overactive bladder market - particularly urge urinary incontinence (UUI). However, as the UUI market becomes increasingly crowded, product differentiation is key. By focusing on the urgency and frequency of symptoms, companies may be able to tap into an under-served market niche.

--Stress urinary incontinence (SUI) is considered the most common subtype of urinary incontinence, but poor awareness and limited treatment options have impacted presentation, diagnosis and treatment rates. The recent approval of duloxetine in the EU presents physicians with a much-needed treatment alternative, but uptake has been slow.

--Poor understanding of the underlying causes of interstitial cystitis (IC) have made diagnosis, management and development of effective drugs for this disorder difficult. With many physicians resorting to treatments that are not specifically approved for IC, experts in the field believe that this could be leading to suboptimal treatment outcomes.

Reasons to order your copy:

--Forecast product sales by understanding key aspects of epidemiology, diagnosis and treatment

--Gain a better understanding of the challenges facing current and future players in the overactive bladder and urinary incontinence market

--Identify physicians' key concerns including unmet needs and the attributes that physicians believe are desirable for future treatments

Companies Mentioned

ALZA Corporation

Boehringer Ingelheim GmbH

Eli Lilly and Company 

GlaxoSmithKline Plc

Kyorin Pharmaceutical Co., Ltd.

Merck & Co., Inc.

Nippon Shinyaku Co., Ltd.

Novartis AG

Pfizer Inc

Sanofi-Aventis Group

Schwarz Pharma AG

Sepracor Inc.

Tanabe Seiyaku Co. Ltd

For more information visit http://www.researchandmarkets.com/reports/c41991

Source: Datamonitor